US equities |
MU $1,043.53 ▼-4.09% NVDA $230.85 ▼-2.79% SNDK $1,612.26 ▼-4.74% AMD $618.00 ▼-4.31% INTC $106.29 ▼-6.04% SPCX $162.26 ▼-3.19% META $719.22 ▼-0.29% PLTR $197.28 ▲+1.63%
FinancialContent

AbCellera Biologics Inc. - Common Shares (NQ:ABCL)

12.11 -0.72 (-5.65%)
Delayed Quote Updated: 2:35 PM EDT, Oct 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbCellera Biologics Inc. - Common Shares

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
Galaxy Digital, Blaize Holdings, Verizon And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025
From AbCellera Biologics Inc.
Via Business Wire
News headline image
Why AbCellera Biologics Stock Raced Nearly 6% Higher Today ↗
Via The Motley Fool
News headline image
Earnings Scheduled For May 8, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 27, 2025 ↗
 
Via Benzinga
News headline image
AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera’s Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Reports Q1 2025 Business Results
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera to Participate at Upcoming Investor Conferences in May and June
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Biologics (ABCL) Q4 2024 Earnings Call Transcript ↗
ABCL earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
AbCellera Reports Full Year 2024 Business Results
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera to Participate at Upcoming Investor Conferences in March
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera to Report Full Year 2024 Financial Results on February 27, 2025
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera to Present at Upcoming Investor Conferences in December and January
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Biologics (ABCL) Q3 2024 Earnings Call Transcript ↗
ABCL earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
AbCellera Reports Q3 2024 Business Results
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera to Present at Upcoming Investor Conferences in November 2024
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AI-Focused Drug Discovery Stocks +6% Last Week Vs. -8% Previous Week ↗
The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 which should result in as many as 50 novel therapies being brought to market by then and generate annual... 
Via Talk Markets
News headline image
AI-Focused Drug Discovery Stocks Portfolio -8% W/e Sept 6th ↗
The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 and should result in as many as 50 novel therapies being brought to market by then and generate annual... 
Via Talk Markets
News headline image
Our AI-Focused Drug Discovery Stocks Portfolio Down 8% In August; Down 6.7% Yesterday Alone! ↗
The August ISM manufacturing index reported on Tuesday that figures came in below consensus expectation. That raised fears about the strength of the economy, driving down our Our AI-Focused Drug... 
Via Talk Markets
Topics Economy
News headline image
AbCellera to Present at Upcoming Investor Conferences in September
From AbCellera Biologics Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >